|
|
General
|
| |
Clinical Use:
|
Emicizumab is a bispecific monoclonal antibody that simultaneously binds to FIXa and FX, restoring the natural haemostatic process thereby acting as a factor VIII-mimetic agent in people with haemophilia A.
Emicizumab has no protease activity (co-factor) and has a half-life of 4-5 weeks. It is administered by weekly subcutaneous injection and is not neutralised by anti-FVIII antibodies (inhibitors).
The assay can be used to monitor emicizumab levels to assist in patient management and adherence. |
| |
Availability:
|
Samples are tested Monday - Friday.
Please contact testing laboratory for urgent requests. |
| |
Aliases/Synonyms:
| Hemlibra, |
| |
Code:
|
EMI |
| |
Handling Instructions (to laboratory):
|
Send whole sample ambient.
Send separated sample frozen on dry ice. |
| |
Hyperlink:
|
|
| |
Reference Interval:
|
Refer to report or laboratory
|
Collection Requirements
|
| |
Container:
|
Sodium Citrate-3.2% (BLUE), |
| |
Sample Type:
|
See container |
| |
Minimum Collection Volume:
|
2.7mL |
| |
Collection Instructions:
|
If sample will not reach testing laboratory within 4 hours of collection, it must be centrifuged, separated and frozen. |
Processing Requirements
|
| |
Alternate Containers:
|
|
| |
Processing Instructions:
|
|
| |
Minimum Assay Volume:
|
1mL |
| |
Stability:
|
4 hours ambient |
| |
Transport Instructions (to testing laboratory):
|
Send whole sample ambient.
Send separated sample frozen on dry ice. |
Testing Locations
|
| |
Performed at:
|
|
Section
|
Department
|
Site
|
Contact Phone
|
| Coagulation |
Haematology |
Fiona Stanley Hospital |
6152 8135 |
| Coagulation |
Haematology |
QEII Medical Centre |
6383 4006 |
|
Last Updated : 07-12-2023 08:08 |